Biotech company Cellevate has launched its lead product, Cellevat3d, in the US.
The nanofibre microcarriers are designed to enhance the yield and productivity of cell cultures suitable for gene therapies, iPSCs, organoids, recombinant proteins and vaccines.
Cellevat3d launched on the first day of the Viral Vector Process Development & Manufacturing Summit, which is currently occurring in Boston, Massachusetts.
This follows the technology's successful European pre-launch in November 2024, which was announced at BIO Europe in Stockholm, Sweden.
According to Cellevat, its stirred tank bioreactor-compatible nanofibre microcarriers have 60x the surface area of conventional cell growth systems, assisting companies in the upstream bioprocessing of viral vector-based applications.
CEO of Cellevate, Laura Chirica commented: “Expanding into the US this soon after our European pre-launch event is a response to the overwhelming market need for innovative, disruptive yet scalable and sustainable technologies in biomanufacturing that provide high yields and faster processes with high productivity."
"We have the potential to revolutionise cell culture applications with Cellevat3d® nanofiber cell culture systems and the therapeutic classes associated with them: at this year’s VVPDM Summit, we will showcase this.”